ArticleNature medicine2019
ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.
Abstract read
In one paragraph
Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed
11.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 216 citations in OpenAlex.
- Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients.Frontiers in immunology · 2025Trial
- From Somatic Driver to Molecular Therapy in Retinal, Choroidal and Periocular Vascular Disease: Mosaicism, Targetable Pathways and Ocular Toxicity.International journal of molecular sciences · 2026Review
- A‑Raf: A serine/threonine protein kinase with important biological functions (Review).Molecular medicine reports · 2026Review
- Lymphatic Imaging and Interventions in Children: Current Practice.Cardiovascular and interventional radiology · 2026Review
- RAS-PI3Kα signaling regulates KrasG12D-induced lymphangiogenesis in complex lymphatic anomalies.Disease models & mechanisms · 2026Article
- SHOC2 Is a Novel Cause of Central Conducting Lymphatic Anomaly.American journal of medical genetics. Part A · 2026Article
- Trametinib Therapy for Hypertrophic Cardiomyopathy and Pulmonary Hypertension in a Child With RAF1-Related Noonan Syndrome (p.Ser257Leu): A Case Report.Clinical case reports · 2026Article
- Lymphatic Malformations With Activating KRAS Mutations Impair Lymphatic Valve Development Through Matrix Metalloproteinases.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Multidimensional single-cell analysis reveals immune dysfunction and inflammatory response in lymphatic malformations.Protein & cell · 2026Article
- MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASPediatric blood & cancer · 2026Article
- Insights into KIF11 pathogenesis in microcephaly-lymphedema-chorioretinopathy syndrome from a lymphatic perspective.JCI insight · 2026Article
- RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.PloS one · 2026Article
- Effects of MEK-inhibitor treatment in infants with lymphatic abnormalities in noonan syndrome.Frontiers in pediatrics · 2026Article
- Expansion of the Phenotype of Lymphatic Anomalies Caused by Somatic Activating BRAF Variant.Pediatric blood & cancer · 2025Article
- Zebrafish Models of Induced Lymphangiogenesis: Current Advancements and Therapeutic Discovery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Oncogenic Activity and Sorafenib Sensitivity ofCancers · 2025Article
- Targeted Therapy for Complex Lymphatic Anomalies in Patients with Noonan Syndrome and Related Disorders.International journal of molecular sciences · 2025Article
- Efficacy of Sirolimus in Treating Refractory Lymphatic Malformation in Noonan Syndrome: A Case Study.JCEM case reports · 2025Article
- MR Lymphangiography in Pediatrics: Indications, Technique, Findings, and Management.Seminars in interventional radiology · 2025Review
- DDX24 spatiotemporally orchestrates VEGF and Wnt signaling during developmental angiogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 6 institutions in 2 countries.
Dong LiCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Michael E MarchCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Alvaro Gutierrez-UzquizaCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Charlly KaoCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Christoph SeilerZebrafish Core Facility, The Children's Hospital of Philadelphia Research Institute, Philadelphia, PA, USA.
Erin PintoCenter for Lymphatic Imaging and Interventions, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Leticia S MatsuokaCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Mark R BattigCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Elizabeth J BhojCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Tara L WengerDivision of Craniofacial Medicine, Seattle Children's Hospital, Seattle, WA, USA.
Lifeng TianCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Nora RobinsonCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Tiancheng WangCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Yichuan LiuCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Brant M WeinsteinDivision of Developmental Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Matthew SwiftDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.
Hyun Min JungDivision of Developmental Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Courtney N KaminskiCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Rosetta ChiavacciCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Jonathan A PerkinsDivision of Otolaryngology-Head and Neck Surgery, Seattle Children's Hospital, Seattle, WA, USA.
Michael A LevineDivision of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Patrick M A SleimanCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Patricia J HicksDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Janet T StrausbaughDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jean B BelascoDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Yoav DoriCenter for Lymphatic Imaging and Interventions, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Hakon HakonarsonCenter for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. hakonarson@email.chop.edu.ORCID http://orcid.org/0000-0003-2814-7461
Children's Hospital of Philadelphia · USNational Institutes of Health · USSeattle Children's Hospital · USUniversity of Pennsylvania · USGeorgetown University · USUniversidad Complutense de Madrid · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of lymphatic anomaly, a rare devastating disease spectrum of mostly unknown etiologies, depends on the patient manifestations
Indexed as
MutationAdultAnimalsChildExome SequencingFemaleHEK293 CellsHumansLymphatic AbnormalitiesMaleMitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins A-rafPyridonesPyrimidinonesZebrafishMitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins A-rafPyridonesPyrimidinonestrametinib
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.